Eyes On The MedTechDev Sector
The MedTechDev Sector has had its ups-and-downs over the past few years – will 2023+ bring a turnaround?
Home »
Robin Bateman
Eyes On News Snippets In Our View
We’ve got eyes on Pre-Earnings news snippets on HIV & RSV Vaccines, Diabetes & Obesity, and New Year M&A.
Eyes On Reviews & Previews for BioPharma & MedTech
Eyes On Reviews and Previews for 2022 & 2023
Catching Up on current events
Eyes On the latest happenings in BioPharma – Approvals, ReSubmissions, and Withdrawals
Watching the Hematology Space
Recently, we’ve had Eyes On the Hema space – trying to keep up with the latest data and approvals for Hemophilia, Sickle Cell, and Beta Thalassemia. The therapies from BioMarin, bluebird bio, and Vertex are set to change the way these diseases are managed and hopefully provided a much needed improvement for patients.
Updated Intel: US Infant Formula Shortage + Zantac Litigation
Eyes On the latest Intel on Zantac Litigation and the FDA investigation into the US Baby Formula Shortage
Novo Nordisk Acquires Forma Therapeutics
This week we had Eyes On the acquisition of Forma Therapeutics by Novo Nordisk – a typically reticent player in the M&A arena.
Heartburn from Zantac
This week the PharmaTell Team had Eyes On Zantac Litigation Causing Heartburn for Legacy Companies
Amazon + One Medical
This week the PharmaTell Team had Eyes On Pharma Tech Outlook …
PharmaTell Is In the Top 10!
This week the PharmaTell Team had Eyes On Pharma Tech Outlook …